SavranTech Receives FDA Breakthrough Device Designation for Urine-Based Assay for Early Risk Stratification of Preeclampsia

SavranTech Welcomes New Advisors to Strengthen Clinical and Strategic Leadership

SavranTech to Present Results of Preeclampsia Study at SRI 2026 Conference

SavranTech Awarded Another U.S. Patent for Automated Cell Capture Technology